bf/NASDAQ:GRCL_icon.jpeg

NASDAQ:GRCL

Gracell Biotechnologies Inc.

  • Stock

USD

Last Close

10.24

21/02 21:00

Market Cap

965.02M

Beta: −1.83

Volume Today

6.37M

Avg: 131.30K

PE Ratio

−12.25

PFCF: -

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019...Show More

Earnings

Earnings per Share (Estimate*)

-2-1.5-1-0.52019-12-312021-03-092022-03-142023-03-132024-03-11

Revenue (Estimate*)

100K200K300K400K2019-12-312021-03-092022-03-142023-03-132024-03-11

*Estimate based on analyst consensus